美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Braveheart Bio

20.36

+0.34001.70%

成交量：15.51万

成交额：314.63万

市值：18.33亿

市盈率：-1.39

高：20.78

开：20.17

低：19.22

收：20.02

52周最高：32.00

52周最低：17.86

股本：9,003.90万

流通股本：2,583.17万

量比：0.32

换手率：0.60%

股息：- -

股息率：- -

每股收益(TTM):-14.6845

每股收益(LYR):-17.2003

净资产收益率：--

总资产收益率：--

市净率：-19.11

市盈率(LYR):-1.18

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

Braveheart Bio

交易所：

NASDAQ

成立时间：

2024

员工人数：

49

公司地址：

One Letterman Drive,Building A,Suite A4-300,San Francisco,California,United States

官网：

http://www.braveheart.bio

邮编：

94129

电话：

传真：

- -

简介：

Braveheart Bio, Inc.于2024年5月13日根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司，专注于为肥厚型心肌病和其他严重心血管疾病患者开发疗法。其主导候选产品BHB-1893是一种下一代口服小分子心肌肌球蛋白抑制剂，由江苏恒瑞医药有限公司获得全球授权，不包括大中华区，并已在恒瑞主要在中国和澳大利亚进行的临床试验中进行评估。

董事

名称

职位

Christopher Viehbacher

Chairman of the Board and Director

Travis Murdoch

Chief Executive Officer, President and Director

David C. Lubner

Director

David Malek

Director

Erez Chimovits

Director

Jason Coloma

Director

Jasper Bos

Director

Tim Lohoff

Director

Vineeta Agarwala

Director

股东

名称

职位

Travis Murdoch

Chief Executive Officer, President and Director

J. Paul Rickey

Chief Financial Officer

Emil deGoma

Chief Medical Officer

Marc Evanchik

Chief Scientific Officer

Michele Anderson

Chief Development Officer

Tyler Chavez

Chief Business Officer

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/BRVE/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BRVE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BRVE\",,,,,undefined,":{"symbol":"BRVE","market":"US","secType":"STK","nameCN":"Braveheart Bio","latestPrice":20.36,"timestamp":1791835200000,"preClose":20.02,"halted":0,"volume":155072,"delay":0,"changeRate":0.016983016983016977,"floatShares":25831738,"shares":90039000,"eps":-14.684527,"marketStatus":"盘前交易","change":0.34,"latestTime":"10-13 05:50:02 EDT","open":20.17,"high":20.78,"low":19.219,"amount":3146308,"amplitude":0.077972,"askPrice":22.46,"askSize":100,"bidPrice":16.82,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-14.684527,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791898200000},"marketStatusCode":1,"adr":0,"listingDate":1785988800000,"exchange":"NASDAQ","adjPreClose":20.36,"postHourTrading":{"tag":"盘后","latestPrice":20.25,"preClose":20.36,"latestTime":"16:26 EDT","volume":9450,"amount":192376.66,"timestamp":1791836780624,"change":-0.11,"changeRate":-0.005403,"amplitude":0.005403},"volumeRatio":0.3151043729827761},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BRVE\",,,,,undefined,":{"symbol":"BRVE","floatShares":25831738,"roa":"--","roe":"--","lyrEps":-17.200311,"volumeRatio":0.3151043729827761,"shares":90039000,"dividePrice":0,"high":20.78,"amplitude":0.077972,"preClose":20.02,"low":19.219,"week52Low":17.86,"pbRate":"-19.11","week52High":32,"institutionHeld":0,"latestPrice":20.36,"eps":-14.684527,"divideRate":0,"volume":155072,"delay":0,"ttmEps":-14.684527,"open":20.17,"prevYearClose":18,"prevWeekClose":20.02,"prevMonthClose":20.2,"prevQuarterClose":20.2,"fiveDayClose":21.35,"twentyDayClose":27.02,"sixtyDayClose":18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BRVE\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BRVE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BRVE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1789099200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BRVE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BRVE","date":"2026-10-12","current":-1.386493,"percent":0.723404,"low":-23.993466,"twenty":-22.008406,"median":-19.658668,"eighty":-16.265628,"high":-12.297967,"avg":-19.216044,"sd":2.96242,"marketCap":1634252980},"quantilePoints":[{"date":"2026-08-07","current":-22.904964,"twenty":-19.277064,"median":-13.835213,"eighty":-12.912865,"marketCap":1837733965},{"date":"2026-08-14","current":-20.770344,"twenty":-22.55018,"median":-20.842324,"eighty":-16.302149,"marketCap":1666466982},{"date":"2026-08-21","current":-21.930028,"twenty":-22.591769,"median":-21.618113,"eighty":-20.309669,"marketCap":1759511923},{"date":"2026-08-28","current":-22.281932,"twenty":-22.249941,"median":-22.006007,"eighty":-20.827928,"marketCap":1787746250},{"date":"2026-09-04","current":-21.010278,"twenty":-22.169963,"median":-21.930028,"eighty":-20.827928,"marketCap":1685717659},{"date":"2026-09-11","current":-18.437402,"twenty":-22.185958,"median":-21.618113,"eighty":-20.469626,"marketCap":1748603206},{"date":"2026-09-18","current":-18.748639,"twenty":-22.118777,"median":-21.390175,"eighty":-18.607905,"marketCap":1778120911},{"date":"2026-09-25","current":-16.155238,"twenty":-22.096383,"median":-21.010278,"eighty":-18.113986,"marketCap":1532162790},{"date":"2026-10-02","current":-18.612348,"twenty":-22.049995,"median":-20.582395,"eighty":-16.309906,"marketCap":1765195108},{"date":"2026-10-09","current":-16.431212,"twenty":-22.013205,"median":-19.756776,"eighty":-16.210433,"marketCap":1558336133},{"date":"2026-10-12","current":-17.231685,"twenty":-22.008406,"median":-19.658668,"eighty":-16.265628,"marketCap":1634252980}],"updateTime":1791882381044},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1959705903,"yearFounded":2024,"employeeNum":49,"address":"One Letterman Drive,Building A,Suite A4-300,San Francisco,California,United States","zipCode":"94129","officePhone":"415 707 6312","fiscalYearEnd":"12-31"},"stockCompanyDetail":{"websiteUrl":"http://www.braveheart.bio","stockEarnings":[{"period":"1week","weight":-0.0464},{"period":"1month","weight":-0.2357},{"period":"3month","weight":0.1311},{"period":"ytd","weight":0.1311}],"compareEarnings":[{"period":"1week","weight":0.0042},{"period":"1month","weight":0.0181},{"period":"3month","weight":0.0349},{"period":"6month","weight":0.1117},{"period":"1year","weight":0.1915},{"period":"ytd","weight":0.141}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Braveheart Bio, Inc.于2024年5月13日根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司，专注于为肥厚型心肌病和其他严重心血管疾病患者开发疗法。其主导候选产品BHB-1893是一种下一代口服小分子心肌肌球蛋白抑制剂，由江苏恒瑞医药有限公司获得全球授权，不包括大中华区，并已在恒瑞主要在中国和澳大利亚进行的临床试验中进行评估。","exchange":"NASDAQ","name":"Braveheart Bio","nameEN":"Braveheart Bio"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"BRVE\",market:\"US\",,,undefined,":{"directors":[{"name":"Christopher Viehbacher","position":"Chairman of the Board and Director"},{"name":"Travis Murdoch","position":"Chief Executive Officer, President and Director"},{"name":"David C. Lubner","position":"Director"},{"name":"David Malek","position":"Director"},{"name":"Erez Chimovits","position":"Director"},{"name":"Jason Coloma","position":"Director"},{"name":"Jasper Bos","position":"Director"},{"name":"Tim Lohoff","position":"Director"},{"name":"Vineeta Agarwala","position":"Director"}],"executives":[{"name":"Travis Murdoch","position":"Chief Executive Officer, President and Director"},{"name":"J. Paul Rickey","position":"Chief Financial Officer"},{"name":"Emil deGoma","position":"Chief Medical Officer"},{"name":"Marc Evanchik","position":"Chief Scientific Officer"},{"name":"Michele Anderson","position":"Chief Development Officer"},{"name":"Tyler Chavez","position":"Chief Business Officer"}]}}}